# Ranok Therapeutics (Hangzhou)

Source: https://onco.cc/companies/ranok-therapeutics-hangzhou/  
OnCo record `ranok-therapeutics-hangzhou` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ranok Therapeutics (Hangzhou) is a China-based biotechnology company running 2 late-stage cancer trials of RNK08954-01 and RNK05047 in sarcomas and diffuse large B-cell lymphoma.

## Summary

Ranok Therapeutics (Hangzhou), based in Hangzhou, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing RNK08954-01 and RNK05047 in sarcomas and diffuse large B-cell lymphoma. The largest, NCT06667544 (A Study of RNK08954 in Subjects With Advanced Solid Tumours With KRAS ((Kirsten Rat Sarcoma) G12D Mutation), plans to enrol 152 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Ranok Therapeutics (Hangzhou) Co., Ltd.; Ranok Therapuetics Co. Ltd.
- Tags: ctgov-sponsor
- HQ: Hangzhou
- Type: biotech
- Website: https://www.ranoktherapeutics.com/

## Sources

- Official website: https://www.ranoktherapeutics.com/
- ClinicalTrials.gov: trials led by Ranok Therapeutics (Hangzhou): https://clinicaltrials.gov/search?lead=Ranok%20Therapeutics%20(Hangzhou)%20Co.%2C%20Ltd.

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [RNK05047](https://onco.cc/drugs/rnk05047/)
- trials: [A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)](https://onco.cc/trials/nct05487170/), [A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation](https://onco.cc/trials/nct06667544/), [IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07441174/)

---
JSON: https://onco.cc/api/v1/entities/ranok-therapeutics-hangzhou.json